Journal of Korean Society for Clinical Pharmacology and Therapeutics (임상약리학회지)

Korean Society for Clinical Pharmacology and Therapeutics (대한임상약리학회)
권호 표지

Effect of Mesoglycan and Aspirin Combination vs Aspirin Alone on Fibrinogen Plasma Levels in Patients with Previous Ischemic Stroke - a Randomized Double Blind Placebo-controlled Trial

허혈성 뇌졸중환자에 있어서, 메조글라이칸(Mesoglycan)과 아스피린 복합요법과 아스피린 단독요법의 피브리노젠 혈장 농도에 미치는 영향 연구- 무작위배정 이중 맹검 위약-대조 연구

  • Min, Joo-Hong (Department of Neurology, Seoul National University Hospital) ;
  • Lee, Soon-Tae (Department of Neurology, Seoul National University Hospital) ;
  • Cho, Joong-Yang (Department of Neurology, Inje University Ilsan Hospital) ;
  • Hong, Yoon-Ho (Department of Neurology, Seoul National University Boramae Hospital) ;
  • Lee, Kwang-Woo (Department of Neurology, Seoul National University Hospital)
  • 민주홍 (서울대학교병원 신경과학교실) ;
  • 이순태 (서울대학교병원 신경과학교실) ;
  • 조중양 (인제대학교 일산백병원 신경과) ;
  • 홍윤호 (서울대학교 보라매병원 신경과학교실) ;
  • 이광우 (서울대학교병원 신경과학교실)
  • Published : 2005.06.30

⟨ Previous Next ⟩

Abstract

Background : Mesoglycan, a preparation of natural glycosaminoglycans, has pleiotropic protective effects on cerebral vasculature, including anti-thrombotic, fibrinolytic and anti-atherogenic activity. It also has shown a feasible potential in the secondary prevention for cerebral ischemia, In this study. we investigated the effect of mesoglycan and aspirin combination on fibrinogen levels in patients with previous ischemic stroke. Methods : Patients with previous ischemic stroke were randomly assigned as either mesoglycan group (mesoglycan 50mg twice daily + aspirin 300mg once daily) or control group (placebo twice daily + aspirin 300mg once daily), and treated in double-blinded manner. Efficacy variable included the fibrinogen level, which was checked on every visit for 8 weeks (at the second, forth and eighth week). Results : Forty-five outpatients (22 control group and 23 mesoglycan group) were included and analyzed. There was no significant difference in the baseline characteristics, including age, sex, baseline fibrinogen and cholesterol profiles, between the mesoglycan group and the control group, No clinical or laboratory adverse effects were reported in the mesoglycan group, while two non-treatment emerging adverse effects were reported in the control group. Mesoglycan group exerted no significant change of the fibrinogen level compared with the control group. Conclusions: In this study, mesoglycan and aspirin combination in patients with previous cerebral ischemia showed a favorable tolerability without any adverse effects. However, to verify the efficacy of mesoglycan and aspirin combination on the fibrinolytic system or the secondary prevention, further study is warranted based on a larger scaled subjects and long-term period.

Keywords